EVIDENCE
Evidence - OPEP and Exacerbation Reduction in COPD
Summary of exacerbation and utilisation evidence.
Finding
A real-world matched cohort of 810 COPD patients showed lower 30-day exacerbation and hospitalisation rates with an OPEP device versus standard care (Burudpakdee, 2017).
Why It Matters
Exacerbations drive most COPD morbidity and cost; reducing them is clinically and economically meaningful.
Caveat
Real-world matched-cohort evidence; a local pilot generates your own outcome data.
Next step Full product documentation and references on request. Health Brands SA - airphysio.co.za.
Get AirPhysio® — R945 incl. 15% VAT
Drug-free airway clearance. Fulfilled by the official SA store.
This platform records measurements taken by your health practitioner and readings you self-report. It does not diagnose or treat any condition. AirPhysio® is a trademark of its manufacturer; claims are limited to airway clearance and lung-expansion support. Items requiring specialist confirmation are marked for review before external use.